Neuroprotection: gut-brain peptide vs neurotrophic mix

BPC-157 vs Cerebrolysin

Comparing BPC-157 and Cerebrolysin across evidence, dosing, mechanisms, and research areas.

vs
Category
healingrecovery
cognitive
Molecular weight
1419.53 g/mol
Half-life
~4 hours (stable in gastric juice — unique among peptides)
Admin routes
subcutaneousintramuscularoraltopical
Research areas
Tendon/ligament repairGut healing (IBD, ulcers, leaky gut)Muscle injury recoveryNeuroprotectionBone fracture healingWound healingOrgan protection (liver, pancreas, heart)
Typical dosing
250–500 mcg · 1-2x daily · 4-12 weeks
FDA status
Not FDA-approved. Category 2 per FDA's 503A bulk drug substance framework (demonstrably difficult to compound). Previously Category 1 as of Feb 2026 reclassification — verify current status.
not-FDA-approved
WADA status
Prohibited (S0 category — non-approved substances, effective January 2022)
PubMed studies
213